Dermatological Drugs Industry

The global dermatological drugs market size is expected to reach USD 42.3 billion by 2030, expanding at a CAGR of 10.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The global dermatological drugs market is expected to grow due to driving factors such as the availability of medical resources for detecting and treating skin diseases, nutritional deficiency due to unhealthy food habits, increasing awareness when it comes to lifestyle diseases, and increasing pollution levels, and lack of immunity in the population. Additionally, the rising per capita income and the increasing purchasing power are the driving forces in this market.

The acne segment is expected to expand with a CAGR of 10.5% from 2022 to 2028. Acne is a skin condition where dead skin and oil glands of skin glands are clogged, forming spots, pimples, and sometimes cysts. Additionally, infected hair follicles cause acne, which starts from the skin’s pores. Acne causes bumps on the face, shoulders, chest, and back in the form of pimples, blackheads, and whiteheads. Acne can be cured, and the appearance of the skin can be improved with effective treatment from dermatologists, contributing to the dermatological drug market.

North America held the largest revenue share of more than 35% in 2021. The U.S. is positively contributing to the growth of the regional market. The presence of well-established pharmaceutical vendors is one of the key factors supporting the market growth. This region is one of the promising regions to launch new technology in terms of healthcare infrastructure and advanced research and development activities that help innovate and produce the most appropriate drugs to cure cancer. It is observed that in the region, there is a rapid shift in the healthcare industry to consumer-driven from traditional treatment for providing diagnosis and provision-based health services. Additionally, ease of availability of drugs and reimbursement policies for the patient in the healthcare industry contributes to driving the market in the region.

Gather more insights about the market drivers, restrains and growth of the Global Dermatological Drugs market

Dermatological Drugs Market Segments Highlights:

  • The psoriasis segment dominated the market with the largest revenue share of 50.6% in 2024, which can be attributed to the awareness of the disease and the demand for effective treatments.
  • The prescription segment dominated the market for the largest revenue share of 61.9% in 2024 and is expected to grow over the fastest CAGR of 10.4% over the forecast period.
  • Topical administration dominated the market with the largest revenue share of 60.0% in 2024.
  • Corticosteroids dominated the market with the largest revenue share of 30.1% in 2024. This can be attributed to rising skin infection cases and the growth of research and development.
  • Retail pharmacies dominated the market, with the largest revenue share of 50.6% in 2024. This can be attributed to OTC dermatological product growth and awareness of skin conditions.
  • The dermatological drugs market in North America dominated the market with the largest revenue share of 38.6% in 2024, which can be attributed to advancements in drug development and increasing awareness.
  • The North America Dermatological Drugs market had the largest revenue share of 33.6% in 2024.

Dermatological Drugs Market Report Segmentation

Grand View Research has segmented the global dermatological drugs market on the basis of therapy, type, route of administration, drug class, distribution channel, and region:

Dermatological Drugs Therapy Outlook (Revenue, USD Million, 2018 - 2030)

  • Acne
  • Psoriasis
  • Rosacea
  • Alopecia
  • Others

Dermatological Drugs Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Prescription
  • Over-the-counter (OTC)

Dermatological Drugs Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Topical Administration
  • Oral Administration
  • Parenteral Administration

Dermatological Drugs Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Corticosteroids
  • Retinoids
  • Antibiotics
  • Antifungals
  • Calcineurin Inhibitors
  • Others

Dermatological Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Dermatological Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Key Dermatological Drugs Company Insights

  • AbbVie Inc.
  • Pfizer Inc.
  • GSK plc.
  • Sun Pharmaceutical Industries Ltd.
  • GALDERMA
  • Amgen Inc.
  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • Almirall, S.A
  • Bausch Health Companies Inc.

Order a free sample PDF of the Dermatological Drugs Market Intelligence Study, published by Grand View Research.